Christi Waarich - Cogent Biosciences Senior Relations
| COGT Stock | USD 9.58 0.05 0.52% |
Executive
Christi Waarich is Senior Relations of Cogent Biosciences
| Address | 275 Wyman Street, Waltham, MA, United States, 02451 |
| Phone | 617 945 5576 |
| Web | https://www.cogentbio.com |
Cogent Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.4402) % which means that it has lost $0.4402 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7847) %, meaning that it created substantial loss on money invested by shareholders. Cogent Biosciences' management efficiency ratios could be used to measure how well Cogent Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.64 in 2024. Return On Capital Employed is likely to drop to -0.79 in 2024. At this time, Cogent Biosciences' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 14.4 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 21.1 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David Liu | Protagonist Therapeutics | 74 | |
| FACC MD | Kiniksa Pharmaceuticals | 59 | |
| Sharon Klahre | Syndax Pharmaceuticals | N/A | |
| Richard Mulligan | Sana Biotechnology | 69 | |
| Naseem MD | Olema Pharmaceuticals | 51 | |
| Mick OQuigley | Ideaya Biosciences | N/A | |
| Timothy Lowinger | Mersana Therapeutics | 60 | |
| Chuck Miller | Mersana Therapeutics | N/A | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
| Sonja MD | Sana Biotechnology | 49 | |
| Mollie MD | Kura Oncology | N/A | |
| JD Moriarty | Olema Pharmaceuticals | 56 | |
| Martina Struck | Kiniksa Pharmaceuticals | N/A | |
| Paul Barsanti | Ideaya Biosciences | N/A | |
| Ryan Baker | Kalvista Pharmaceuticals | N/A | |
| Kavita Aggarwal | Verona Pharma PLC | N/A | |
| John Berman | Larimar Therapeutics | N/A | |
| Richard Shames | Protagonist Therapeutics | 64 | |
| Kathleen MD | Verona Pharma PLC | 66 | |
| Terry MD | Sana Biotechnology | 57 | |
| John Paolini | Kiniksa Pharmaceuticals | 59 | |
Management Performance
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.44 |
Cogent Biosciences Leadership Team
Elected by the shareholders, the Cogent Biosciences' board of directors comprises two types of representatives: Cogent Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cogent. The board's role is to monitor Cogent Biosciences' management team and ensure that shareholders' interests are well served. Cogent Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cogent Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sara Saltzman, VP Affairs | ||
| Jessica MD, Chief Officer | ||
| Brad Fell, Senior Chemistry | ||
| Rachael MD, VP Development | ||
| Andrew MBA, CEO President | ||
| Christi Waarich, Senior Relations | ||
| Brad Barnett, Chief Officer | ||
| Erin Schellhammer, Chief Officer | ||
| John Robinson, Chief Officer | ||
| Evan JD, Chief Secretary | ||
| Dana PharmD, Senior Officer |
Cogent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cogent Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.44 | ||||
| Current Valuation | 851.13 M | ||||
| Shares Outstanding | 110.46 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 99.88 % | ||||
| Number Of Shares Shorted | 7.72 M | ||||
| Price To Earning | (5.03) X | ||||
| Price To Book | 5.19 X | ||||
| Price To Sales | 1,321 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.